OraSure Technologies, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. OraSure develops and sells diagnostic tests and specimen collection devices, including rapid HIV and HCV tests, DNA collection systems through DNA Genotek (DNAG), drug-testing products, and cryosurgical products.
Financial performance
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net revenue | $106.5 million | $98.9 million |
| Net product revenue | $98.9 million | $98.3 million |
| Gross profit / margin | $66.6 million / 63% | $58.6 million / 59% |
| Operating loss | $4.8 million | $12.2 million |
| Net loss | $4.6 million | $11.2 million |
| Loss per share, basic and diluted | $0.08 | $0.20 |
| Cash from operating activities | $7.5 million | $8.4 million |
| Cash, cash equivalents and short-term investments, year-end | $97.9 million | $93.2 million |
| Working capital, year-end | $104.8 million | $100.6 million |
Revenue grew 8%, while product revenue rose only 1%; the increase in total revenue was largely due to $7.6 million of licensing and product-development revenue recognized under the AbbVie HCV agreement. There was no long-term debt outstanding at year-end; the company had repaid its debt in 2012. Management said available cash was expected to fund operating and capital needs for at least the next 12 months. The company reported a $178.3 million accumulated deficit and said it had recorded annual net losses since 2008.
Fourth-quarter 2014 revenue was $28.7 million, operating loss was $2.6 million, net loss was $2.7 million, and diluted loss per share was $0.05.
Business and material changes
- Segment performance: OSUR revenue was $82.7 million, up 5% including AbbVie-related revenue; its operating loss was $8.3 million. DNAG revenue was $23.8 million, up 17%, and operating income was $3.5 million.
- Product trends: OraQuick HIV revenue fell 7% to $38.9 million, including a 29% decline in U.S. in-home HIV sales. OraQuick HCV revenue rose 42% to $7.3 million. Cryosurgical revenue increased 7% to $15.5 million, and DNAG molecular collection revenue grew 17% to $23.8 million.
- Domestic professional HIV sales were affected by customer migration to automated fourth-generation laboratory tests under CDC guidance, as well as price competition. The in-home HIV promotional strategy shifted toward retail-level activity and away from broad consumer advertising; related advertising and promotional expense fell to $8.5 million from $18.8 million.
- Gross margin improved to 63%, reflecting AbbVie agreement revenue and a more favorable product mix, including higher-margin DNAG sales. The operating loss also narrowed, helped by lower in-home HIV promotion costs and Roche settlement income.
- Roche termination payments provided a $5.5 million reduction to operating expenses in 2014, compared with $8.3 million in 2013. These are unusual, non-recurring items and affect year-over-year comparability.
- Cash from operations was supported by a $6.9 million increase in deferred revenue, including the AbbVie upfront payment. Inventory increased $4.4 million, partly associated with OraQuick HCV.
Outlook, risks and contingencies
- Under its agreement with AbbVie, OraSure received $15 million in July 2014, recognized $7.6 million in 2014, and reported $7.4 million of the payment as deferred revenue at year-end. The agreement runs through 2019 and provides for up to $75 million in aggregate payments, with additional annual performance-based fees potentially available beginning in 2015. Timing and achievement of milestones are uncertain; early termination could reduce payments.
- The company launched its Intercept i2 oral-fluid drug collection device and assays in 2014; six additional assays were expected to launch in 2015. It also began developing a rapid Ebola test, contingent on external development funding, purchase commitments, successful field testing, and regulatory authorization. OraSure said it might discontinue the Ebola project if key objectives were not met.
- DNAG remained subject to an FDA warning letter concerning documentation of product design and finished-product acceptance testing, including its ORAcollect device. A 510(k) application for ORAcollect was pending. Management expected no material near-term financial impact, but the warning letter remained unresolved.
- Key risks include continuing losses; dependence on government and research funding; competition and price pressure; uncertain adoption of new products and achievement of AbbVie milestones; FDA and other regulatory requirements; and reliance on sole-source suppliers and contract manufacturers. The company also noted increased FDA scrutiny of laboratory-developed tests, which could affect demand for DNAG products.
- Management expected approximately $4.0 million of capital expenditures in 2015. Contractual obligations totaled approximately $14.3 million, including $8.7 million of purchase commitments. The company reported no off-balance-sheet arrangements and said ordinary-course legal matters were not expected to have a material adverse effect.
- Management reported effective disclosure controls and internal control over financial reporting; KPMG issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether the AbbVie co-promotion program drives HCV testing growth and qualifies OraSure for performance-based payments, and how deferred revenue is recognized.
- Whether HIV product declines persist under CDC testing guidance and whether the revised in-home HIV marketing approach can improve sales and profitability.
- The status and resolution of DNAG’s FDA warning letter and ORAcollect clearance application.
- Whether DNAG growth offsets continued pressure in OSUR’s HIV and other product lines, and whether margins are sustainable without settlement gains.
- Whether planned Intercept i2 assay expansion and the Ebola development program achieve expected regulatory, funding, and commercial milestones.
- Potential effects of sole-source supply disruptions, government funding changes, customer purchasing patterns, and foreign-currency movements on cash flow and results.